Matthias Blamont on Muck Rack

Matthias Blamont

Verified
Europe
As seen in: Le Monde, Thomson Reuters, MSN, MSN Australia, MSN Canada, MSN New Zealand, MSN UK, O Globo, UOL, Business Insider, Daily Mail, MSN South Africa and
Likes to ask questions. Editor @LeMonde Ex correspondent @Reuters @LesEchos
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Matthias

Contact Matthias, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exclusive-Sanofi offers to buy U.S. biotech, mRNA partner Translate Bio -sources

|
By Matthias Blamont Verified
| Investing.com
Please try another search More More Stock Markets9 minutes ago (Aug 02, 2021 06:31PM ET) © Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau By Matthias Blamont PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio (NASDAQ:), two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
Open in Who Shared View Duplicates (5) Issue with article?

Exclusive-Sanofi Offers to Buy U.S. Biotech, MRNA Partner Translate Bio -Sources

|
By Matthias Blamont Verified
| U.S. News and World Report Verified
By Matthias Blamont PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
Open in Who Shared View Duplicates (15) Issue with article?

Sanofi raises profit forecast after second quarter beat

|
By Matthias Blamont Verified
| MarketScreener
The French drugmaker said it was now targeting earnings per share growth of around 12% at constant exchange rates this year, up from "high single digit" percentage growth previously. Sanofi, which shocked investors last year with a delay to a COVID-19 vaccine it is developing with Britain's GlaxoSmithKline, reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year.
Open in Who Shared Issue with article?
See all 1,024 licensed articles (1,553 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified